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and was attributable to reduced hepatic glucose production. By 14 d after the surgery, blood glucose remained at or near normal concentrations, whereas the expected marked elevation of blood glucose persisted in shamoperated diabetic rats. These findings indicate that bariatric surgery can resolve diabetes in these nonobese T1D rodent models, in addition to the earlier evidence that it can improve glucose control in a rat model of nonobese streptozotocin-induced diabetes 5 and in rat models of T2D 6, 7 . More importantly, they suggest that the increased delivery of nutrients to the jejunum resulting from DJB can induce substantial lowering of glucose concentrations without increasing insulin secretion.
The notion that intestinal nutrient sensing underlies the rapid diabetes resolution induced by bariatric surgery is not without controversy. For example, many studies have implicated increased insulin secretion in the lowering of glucose concentrations observed after gastric bypass surgery in rat models of T2D 6 . Yet plasma insulin concentrations were not altered by DJB in the study of Breen et al. 3 . Dramatic increases in the concentrations of circulating incretin peptides (primarily glucagon-like peptide-1) have also been invoked to explain the beneficial effects of gastric bypass 7 . Although Breen et al. 3 observed increased Several bariatric, or 'weight loss' , surgical procedures are proving effective for treating not only obesity but also type 2 diabetes (T2D). As obesity is a major risk factor for T2D, it seems logical that treating the former would benefit the latter. Surprisingly, however, these surgeries seem to improve T2D through mechanisms that are at least partly independent of weight loss per se.
Perhaps the best-studied bariatric procedure is Roux-en-Y gastric bypass (RYGB), which both reduces the size of the stomach and bypasses the proximal small intestine (the duodenum and the proximal jejunum; Fig. 1 ). In two recently published randomized trials 1,2 , RYGB was shown to fully normalize blood sugar concentrations in up to 75% of treated patients with T2D, a remarkable outcome that was not strongly related to the degree of weight loss in these individuals. Thus, rerouting of or increasing nutrient delivery to the small bowel (or both) has seemingly important potential as a diabetes treatment modality, but how this occurs remains a mystery. A related question is whether weight-loss surgery is appropriate only in the context of obesity-the condition for which it was originally developed-or whether lean people with insulin-deficient type 1 diabetes (T1D) might also benefit.
In this issue of Nature Medicine, Breen et al. 3 extend their earlier work 4 that suggested that the duodenum senses nutrients when they arrive by showing that a similar arrangement also pertains to the jejunum. Signals generated in response to nutrients in the proximal small bowel are passed on to the brain, which in turn is proposed to activate a neurocircuit innervating the liver that reduces its glucose production. This mechanism has been suggested to ensure that delivery of glucose into the bloodstream from an internal source (the liver) decreases when ingested nutrients arrive at the absorptive surface of the gut. Breen et al. 3 now report in normal-weight, nondiabetic rats that, analogous to what they' d previously reported for the duodenum 4 , infusion of either fats or glucose directly into the jejunum activates a gut-brain-liver neurocircuit that enhances liver insulin sensitivity, thereby reducing hepatic glucose production.
Does this jejunal nutrient-sensing mechanism contribute to the antidiabetic effect of gastric bypass surgery? To investigate this question, Breen et al. 3 investigated the effects of duodenal-jejunal bypass (DJB, a stomachsparing form of RYBG; Fig. 1 ) in two rat models in which diabetes is induced by the substantial destruction of pancreatic beta cells. This was achieved either by administering the beta cell-targeting toxin streptozotocin or through a genetically driven autoimmune process (in BB (BioBreeding) rats). Thus, both models are nonobese and characterized by a major loss of insulin-secreting beta cells, a situation resembling T1D rather than T2D. In both models, DJB rapidly (2 d after surgery) lowered blood glucose concentrations via a mechanism that was not explained by reduced food intake, required intact jejunal nutrient sensing, was not accompanied by increased insulin secretion
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David A Sarruf, Susan Bonner-Weir & Michael W Schwartz Bariatric surgery to treat obesity can also be effective against type 2 diabetes, but it is unclear how such surgical procedures improve glucose metabolism. A new study in rats suggests that nutrient sensing in the jejunum contributes to the antidiabetic effects of duodenal-jejeunal bypass (pages 950-955). Ingested food npg circulating glucagon-like peptide-1 concentrations in response to DJB, this effect should not reduce hepatic glucose production in the absence of increased insulin (or decreased glucagon secretion, which also was not observed). The conclusion of Breen et al. 3 that suppression of hepatic glucose production, resulting solely from activation of a gut-brain-liver reflex arc, is sufficient to ameliorate diabetes is deserving of additional study. Also controversial is the idea that rerouting of intestinal nutrient delivery is required for bariatric surgery to confer metabolic benefit. Data from both rats 8 and humans 2 suggest that sleeve gastrectomy, which restricts the size of the stomach but does not redirect intestinal nutrient flow (Fig. 1) , is nearly as effective as RYGB for resolving diabetes. Combined with evidence that DJB does not improve insulin resistance or glucose tolerance in an obese rat model 9 , rerouting intestinal nutrient delivery may not be essential for the effect of bariatric surgery to lower glucose concentrations-simply increasing the rate of gastric emptying may suffice.
These considerations challenge the primacy of jejunal nutrient sensing as a mediator of diabetes remission induced by bariatric procedures.
Among many important unanswered questions is whether bariatric surgery can be recommended for nonobese humans with T1D. Without more data on the long-term outcomes of such procedures in obese patients with T2D, this question seems premature. Another consideration is that nonobese humans with T1D are likely to have a far greater deficit of beta cells and thus are more insulin deficient than the rat models studied by Breen et al. 3 . Additionally, the role of weight loss (which probably had an impact on outcomes reported by these authors, even though they took steps to minimize this effect) in diabetes resolution is complex and awaits further analysis. So, when might we consider undertaking clinical studies that address the safety, tolerability, efficacy and durability of such surgical procedures in nonobese patients with T1D? Perhaps it is not too soon to consider studies that address these questions, but the existence of a glucose-lowering neurocircuit connecting gut, brain and liver raises the possibility that we might one day develop drugs that activate this pathway without the need for surgery. This possibility offers a compelling rationale for ongoing efforts to identify the mechanisms that underlie the impressive effects of bariatric surgery on glucose homeostasis.
Kaposi's sarcoma-associated herpesvirus (KSHV) causes two types of malignancies: the endothelial tumor eponymously named Kaposi's sarcoma and B cell malignancies including multicentric Castleman's disease and primary effusion lymphoma, in which the virus is associated with plasmablastic and preterminally differentiated B cells, respectively. Various host factors have been found to facilitate KSHV cell entry and establishment of infection (Box 1). However, given that these molecules are predominantly ubiquitously expressed, it is unclear how the virus is lured specifically to cells of the endothelial lineage.
Cell entry is a fundamental component of the biology of any virus. For enveloped viruses such as herpesviruses, cell entry is a multistep process that involves viral envelope glyco proteins as well as several cellular attachment and entry factors (Fig. 1) . The virus envelope proteins have two trafficking, but not necessarily for KSHV attachment to target cells 2 . Together, these results suggest that EphA2 has a crucial role in the infection of endothelial cells by KSHV.
The first Eph receptor was dis covered in 1987 in a cancer cell line called erythropoietinproducing hepatocellular 3 . Eph ligands were dubbed ephrins (Eph receptor-interacting molecules). Ephs are now the largest receptor tyrosine kinase (RTK) family, with 14 known human members. In contrast to most other ligand-RTK interactions that result in activation of the receptor, upon interaction with Eph receptors, membrane-bound ephrins are also activated to produce signals in their host cells, a phenomenon termed reverse signaling, and these signaling pathways can alternately trigger cell repulsion or attraction. In 1998 the focus of research into Ephs moved to vascular development when it was discovered that EphB4 and its ligand, ephrinB2, distinguish veins and arteries, respectively, in the developing vascular bed 4 . EphA2 was shown to be sufficient to transform mammary functions: specific attachment of the virus to the cell and membrane fusion. The KSHV envelope glycoproteins H and L form a dimer (gH-gL) that is necessary for entry into the host cell.
In this issue of Nature Medicine, Hahn et al. 1 report that the ephrin receptor A2 (EphA2) tyrosine kinase specifically binds the KSHV attachment glycoproteins gH and gL, allowing virus entry (Fig. 1) . The authors showed that EphA2 co-precipitates with gH-gL and with KSHV virions in vitro 1 . They then performed a number of experiments to provide convincing evidence that this host cellular molecule functions as a receptor for KSHV: knockdown or deletion of EphA2 inhibited or abolished KSHV infection of endothelial cells, and overexpression of EphA2 enhanced infection; preincubating KSHV virions with soluble EphA2 or pretreating endothelial cells with a soluble EphA2 ligand inhibited infection; and binding of KSHV gH-gL to EphA2 activated EphA2 phosphorylation and promoted endocytosis 1 . This work coincides with the observation that EphA2 is required for KSHV entry and npg
